LLY Eli Lilly plans to file for approval for its next-generation obesity drug in 2027. Lilly also announced that injectable retatrutide, tri

LLY Eli Lilly plans to file for approval for its next-generation obesity drug in 2027. Lilly also announced that injectable retatrutide, triple-acting on the GLP-1, GIP, and glucagon hormones, cleared two late-stage trials with substantial weight loss and improved glycemic control. Lilly told CNBC it needs more time to verify the manufacturing and quality-control data before filing with regulators. - per Cramer Investing Club Newsletter